Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1990 2
1991 2
1992 7
1994 4
1996 6
1997 5
1998 4
1999 5
2000 7
2001 3
2002 7
2003 4
2004 3
2005 6
2006 1
2007 3
2008 3
2009 2
2010 3
2011 6
2012 9
2013 4
2014 10
2015 14
2016 8
2017 14
2018 9
2019 13
2020 16
2021 26
2022 20
2023 10
Text availability
Article attribute
Article type
Publication date

Search Results

215 results
Results by year
Filters applied: . Clear all
Page 1
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Provencio M, Nadal E, Insa A, García-Campelo MR, Casal-Rubio J, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Pereira E, Royuela A, Casarrubios M, Salas Antón C, Parra ER, Wistuba I, Calvo V, Laza-Briviesca R, Romero A, Massuti B, Cruz-Bermúdez A. Provencio M, et al. Among authors: calvo v. Lancet Oncol. 2020 Nov;21(11):1413-1422. doi: 10.1016/S1470-2045(20)30453-8. Epub 2020 Sep 24. Lancet Oncol. 2020. PMID: 32979984 Clinical Trial.
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).
Provencio M, Serna-Blasco R, Nadal E, Insa A, García-Campelo MR, Casal Rubio J, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Pereira E, Royuela A, Calvo V, Martín-López J, García-García F, Casarrubios M, Franco F, Sánchez-Herrero E, Massuti B, Cruz-Bermúdez A, Romero A. Provencio M, et al. Among authors: calvo v. J Clin Oncol. 2022 Sep 1;40(25):2924-2933. doi: 10.1200/JCO.21.02660. Epub 2022 May 16. J Clin Oncol. 2022. PMID: 35576508 Free PMC article. Clinical Trial.
Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling.
Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, García-Grande A, Coronado MJ, Laine-Menéndez S, Alfaro C, Sanchez JC, Franco F, Calvo V, Romero A, Martin-Acosta P, Salas C, Garcia JM, Provencio M. Cruz-Bermúdez A, et al. Among authors: calvo v. Free Radic Biol Med. 2019 Jan;130:163-173. doi: 10.1016/j.freeradbiomed.2018.10.450. Epub 2018 Nov 1. Free Radic Biol Med. 2019. PMID: 30391585 Free article.
Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition.
Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, García-Grande A, Coronado MJ, Laine-Menéndez S, Palacios-Zambrano S, Moreno-Villa MR, Ruiz-Valdepeñas AM, Lendinez C, Romero A, Franco F, Calvo V, Alfaro C, Acosta PM, Salas C, Garcia JM, Provencio M. Cruz-Bermúdez A, et al. Among authors: calvo v. Free Radic Biol Med. 2019 May 1;135:167-181. doi: 10.1016/j.freeradbiomed.2019.03.009. Epub 2019 Mar 14. Free Radic Biol Med. 2019. PMID: 30880247 Free article.
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
Casarrubios M, Provencio M, Nadal E, Insa A, Del Rosario García-Campelo M, Lázaro-Quintela M, Dómine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé R, Viñolas N, Barneto Aranda I, Massuti B, Sierra-Rodero B, Martinez-Toledo C, Fernández-Miranda I, Serna-Blanco R, Romero A, Calvo V, Cruz-Bermúdez A. Casarrubios M, et al. Among authors: calvo v. J Immunother Cancer. 2022 Sep;10(9):e005320. doi: 10.1136/jitc-2022-005320. J Immunother Cancer. 2022. PMID: 36171009 Free PMC article. Clinical Trial.
Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges.
Mielgo-Rubio X, Martín M, Remon J, Higuera O, Calvo V, Jarabo JR, Conde E, Luna J, Provencio M, De Castro J, López-Ríos F, Hernando-Trancho F, Couñago F. Mielgo-Rubio X, et al. Among authors: calvo v. Future Oncol. 2021 Oct;17(30):4011-4025. doi: 10.2217/fon-2020-1255. Epub 2021 Aug 2. Future Oncol. 2021. PMID: 34337973 Review.
GeSnOI mid-infrared laser technology.
Wang B, Sakat E, Herth E, Gromovyi M, Bjelajac A, Chaste J, Patriarche G, Boucaud P, Boeuf F, Pauc N, Calvo V, Chrétien J, Frauenrath M, Chelnokov A, Reboud V, Hartmann JM, El Kurdi M. Wang B, et al. Among authors: calvo v. Light Sci Appl. 2021 Nov 17;10(1):232. doi: 10.1038/s41377-021-00675-7. Light Sci Appl. 2021. PMID: 34785641 Free PMC article.
215 results